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We have read with great interest the article entitled
‘Leukoencephalopathy with brainstem and spinal cord involvement
and lactate elevation: clinical and genetic characterization and
target for therapy’ in the April issue of Brain (Van Berge et al.,
2014). The authors present new data regarding clinical, neuroima-
ging and genetic findings linked to leukoencephalopathy with
brainstem and spinal cord involvement and lactate elevation
(LBSL; MIM #611105), an autosomal recessive inherited leukoen-
cephalopathy caused by compound heterozygous mutations in the
DARS2 gene (1q25.1), which codes the mitochondrial aspartyl-
tRNA synthetase. LBSL represents one of the typical early-onset
leukodystrophies mainly affecting children and juvenile patients
with a slow progressive cerebellar ataxia with spastic paraparesis
(or sometimes only retained reflexes) and findings suggestive of a
posterior cord syndrome (Van der Knaap et al., 2003). Epilepsy,
learning disabilities, axonal peripheral neuropathy (Yamashita
et al., 2013) and mild cognitive compromise have also been
described, although asymptomatic late-onset cases and radiologic-
ally diagnosed patients have also been related. Typical neuroima-
ging pattern is represented by diffuse symmetric non-enhancing
inhomogeneous lesions, hyperintense in T2-weighted images and
hypointense in T1-weighted images, with preponderant supraten-
torial periventricular and subcortical cerebellar lesions, sparing U
fibres. The lateral corticospinal tracts, the medullary pyramids, the
posterior limb of internal capsule, the spinal cord dorsal columns,
the medial lemniscos, the intraparenchymal trigeminal pathways,
the cerebellar peduncles, the splenium of corpus callosum are also
typically involved. The leukodystrophic lesions generally present in
magnetic resonance spectroscopy with high lactate peaks
(Steenweg et al., 2011), although this finding is not pathogno-
monic or required to diagnose LBSL (Sharma et al., 2011). High
lactate in CSF is rarely found.
The authors made a comprehensive and expanded analysis of
clinical features in 66 patients with LBSL (Van Berge et al., 2014).
They revealed that only 12% of patients start their disease after
the age of 18 years, mainly in females. This group showed a slow
progression and most patients presented mild to moderate motor
compromise. They also showed cases of early-onset, generally
with a severe motor phenotype similar to a previous Japanese
study (Miyake et al., 2011), but also a nearly asymptomatic nurs-
ling with neuroradiological and molecular diagnosis of LBSL.
Most patients had compound heterozygous mutations.
Although classically thought as lethal in humans, homozygosity
for a DARS2 mutation was described in this study in severe
early-onset cases, and also in a previous study of a 25-year-old
German female with a paroxysmal recurrent exercise-induced gait
ataxia (Synofzik et al., 2011). Evaluation also disclosed mild distal
position and vibration sense deficits, hyper-reflexia and mild spas-
ticity. Neuroimaging changes resembled those typical of LBSL and
laboratory evaluation showing intermittent increases in serum lac-
tate. This patient also presented with an acetazolamide-responsive
episodic ataxia phenotype, resembling the clinical phenotype of
classical autosomal dominant episodic ataxias.
Taking into account all the previous literature data and findings
of this new study, we propose the use of a new descriptive
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nomenclature more related to the mutated gene, so-called the
‘DARS2-related conditions’ or ‘DARS2-related spectrum disorders’.
We believe that the use of this broader nomenclature may repre-
sent properly the clinical and neuroimaging findings of patients
with different mutations from a single gene. This approach may
also contribute to enrich our knowledge regarding LBSL
pathogenesis.
The authors also started a new therapeutic approach using
direct antisense oligonucleotide cantharidin, an important splicing
modulator, affecting the intron 2/exon 3 event splicing, the most
commonly affected in LBSL. Despite promising results, we propose
new therapeutic approaches regarding the use of acetazolamide
and other carbonic anhydrase partial inhibitors for patients who
present with typical LBSL phenotype or with DARS2 mutations
similarly to the episodic ataxia phenotype previously described
(Synofzik et al., 2011).
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